Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer

  • Kalisz, Mark
  • Bernardo, Edgar
  • Maestro, Miguel Ángel
  • Grau, Vanessa
  • Real, Francisco X.
  • Ferrer, Jorge
Defects in transcriptional regulators of pancreatic exocrine differentiation have been implicated in pancreatic tumorigenesis, but the molecular mechanisms are poorly understood. The locus encoding the transcription factor HNF1A harbors susceptibility variants for pancreatic ductal adenocarcinoma (PDAC), while KDM6A, encoding Lysine-specific demethylase 6A, carries somatic mutations in PDAC. Here, we show that pancreas-specific Hnf1a null mutant transcriptomes phenocopy those of Kdm6a mutations, and both defects synergize with KrasG12D to cause PDAC with sarcomatoid features. We combine genetic, epigenomic, and biochemical studies to show that HNF1A recruits KDM6A to genomic binding sites in pancreatic acinar cells. This remodels the acinar enhancer landscape, activates differentiated acinar cell programs, and indirectly suppresses oncogenic and epithelial-mesenchymal transition genes. We also identify a subset of non-classical PDAC samples that exhibit the HNF1A/KDM6A-deficient molecular phenotype. These findings provide direct genetic evidence that HNF1A deficiency promotes PDAC. They also connect the tumor-suppressive role of KDM6A deficiency with a cell-specific molecular mechanism that underlies PDAC subtype definition., This research was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre. Work was funded by grants from the Wellcome Trust (WT101033 to J.F.), Medical Research Council (MR/L02036X/1 to J.F.), European Research Council Advanced Grant (789055 to J.F.), Ministerio de Ciencia e Innovación (BFU2014‐54284‐R, RTI2018‐095666‐B‐I00 to J.F., SAF2011‐29530 and SAF2015‐70553‐R to F.X.R.) and RTICC from Instituto de Salud Carlos III (RD12/0036/0034, RD12/0036/0050) to F.X.R. M.K. was supported by a Juvenile Diabetes Research Foundation postdoctoral fellowship (3‐PDF‐2014‐192‐A‐N). I.M. was supported by a Fellowship from Fundació Bancaria La Caixa (ID 100010434) (grant number LCF/BQ/ES18/11670009). Work in CRG was supported by the CERCA Programme, Generalitat de Catalunya, and support from Ministerio de Ciencia e Innovación to the EMBL partnership. Work at CRG and CNIO was supported by Centro de Excelencia Severo Ochoa grants SEV‐2012‐0208, SEV‐2016‐0510.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

AID-expressing epithelium is protected from oncogenic transformation by an NKG2D surveillance pathway

  • Pérez García, Arantxa
  • Pérez Durán, Pablo
  • Wossning, Thomas
  • Sernandez, Isora V.
  • Mur, Sonia M.
  • Cañamero, Marta
  • Real, Francisco X.
  • Ramiro, Almudena R.
Activation-induced deaminase (AID) initiates secondary antibody diversification in germinal center B cells, giving rise to higher affinity antibodies through somatic hypermutation (SHM) or to isotype-switched antibodies through class switch recombination (CSR). SHM and CSR are triggered by AID-mediated deamination of cytosines in immunoglobulin genes. Importantly, AID activity in B cells is not restricted to Ig loci and can promote mutations and pro-lymphomagenic translocations, establishing a direct oncogenic mechanism for germinal center-derived neoplasias. AID is also expressed in response to inflammatory cues in epithelial cells, raising the possibility that AID mutagenic activity might drive carcinoma development. We directly tested this hypothesis by generating conditional knock-in mouse models for AID overexpression in colon and pancreas epithelium. AID overexpression alone was not sufficient to promote epithelial cell neoplasia in these tissues, in spite of displaying mutagenic and genotoxic activity. Instead, we found that heterologous AID expression in pancreas promotes the expression of NKG2D ligands, the recruitment of CD8(+) T cells, and the induction of epithelial cell death. Our results indicate that AID oncogenic potential in epithelial cells can be neutralized by immunosurveillance protective mechanisms., AP‐G is a fellow of the research training program (FPU‐ AP2009‐1732) funded by the Ministerio de Educación, Cultura y Deporte, PP‐D was an FPI fellow from the Ministerio de Ciencia e Innovación. ARR is supported by Centro Nacional de Investigaciones Cardiovaculares (CNIC). This work was funded by grants from the Ministerio de Economía y Competitividad (SAF2010‐21394, SAF2013‐42767‐R) and the European Research Council Starting Grant program (BCLYM‐207844) to ARR. The CNIC is supported by the Ministerio de Economía y Competitividad and the Pro‐CNIC Foundation. FXR is supported by SAF2011‐29530 and ONCOBIO Consolider grants from Ministerio de Economía y Competitividad (Madrid, Spain), RTICC from Instituto de Salud Carlos III, and grant 256974 from European Union Seventh Framework Programme to FXR.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

NFIC regulates ribosomal biology and ER stress in pancreatic acinar cells and restrains PDAC initiation

  • Cobo, Isidoro
  • Paliwal, Sumit
  • Bodas, Cristina
  • Felipe, Irene
  • Melià-Alomà, Júlia
  • Torres, Ariadna
  • Martínez-Villarreal, Jaime
  • Malumbres, Marina
  • García, Fernando
  • Millán, Irene
  • Del Pozo, Natalia
  • Park, Joo-Cheol
  • MacDonald, Ray J.
  • Muñoz, Javier
  • Méndez, Raúl
  • Real, Francisco X.
Pancreatic acinar cells rely on PTF1 and other transcription factors to deploy their transcriptional program. We identify NFIC as a NR5A2 interactor and regulator of acinar differentiation. NFIC binding sites are enriched in NR5A2 ChIP-Sequencing peaks. Nfic knockout mice have a smaller, histologically normal, pancreas with reduced acinar gene expression. NFIC binds and regulates the promoters of acinar genes and those involved in RNA/protein metabolism, and Nfic knockout pancreata show defective ribosomal RNA maturation. NFIC dampens the endoplasmic reticulum stress program through binding to gene promoters and is required for resolution of Tunicamycin-mediated stress. NFIC is down-regulated during caerulein pancreatitis and is required for recovery after damage. Normal human pancreata with low levels of NFIC transcripts display reduced expression of genes down-regulated in Nfic knockout mice. NFIC expression is down-regulated in mouse and human pancreatic ductal adenocarcinoma. Consistently, Nfic knockout mice develop a higher number of mutant Kras-driven pre-neoplastic lesions., This work was supported, in part, by grants SAF2011-29530, SAF2015-70553-R, RTI2018-101071-B-I00 from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (co-funded by the ERDF-EU) and RTICC from Instituto de Salud Carlos III (RD12/0036/0034) to FXR and grants PID2020-119533GB-I00, from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain), and GCB15152955MÉND, from the Spanish Association Against Cancer (AECC), to RM. I.C. was recipient of a Beca de Formación del Personal Investigador from Ministerio de Economía y Competitividad (Madrid, Spain). The research leading to these results has received funding from People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007-2013) (REA grant agreement n° 608765”). S.P. was supported by a Juan de la Cierva Programme fellowship from Ministerio de Ciencia, Innovación y Universidades. C.B. is supported by a FPI Fellowship from Ministerio de Ciencia, Innovación y Universidades. I.M. was supported by a Fellowship from Fundació Bancària La Caixa (ID 100010434) (grant number LCF/BQ/ES18/11670009). CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver

  • Hruschka, Natascha
  • Andreu Martínez, David
  • Real, Francisco X.
  • Martinelli, Paola
As the catalog of oncogenic driver mutations is expanding, it becomes clear that alterations in a given gene might have different functions and should not be lumped into one class. The transcription factor GATA3 is a paradigm of this. We investigated the functions of the most common GATA3 mutation (X308_Splice) and five additional mutations, which converge into a neoprotein that we called "neoGATA3," associated with excellent prognosis in patients. Analysis of available molecular data from >3000 breast cancer patients revealed a dysregulation of the ER-dependent transcriptional response in tumors carrying neoGATA3-generating mutations. Mechanistic studies in vitro showed that neoGATA3 interferes with the transcriptional programs controlled by estrogen and progesterone receptors, without fully abrogating them. ChIP-Seq analysis indicated that ER binding is reduced in neoGATA3-expressing cells, especially at distal regions, suggesting that neoGATA3 interferes with the fine tuning of ER-dependent gene expression. This has opposite outputs in distinct hormonal context, having pro- or anti-proliferative effects, depending on the estrogen/progesterone ratio. Our data call for functional analyses of putative cancer drivers to guide clinical application., Work in the lab of PM was supported by the Institute of Cancer Research of the Medical University Vienna and by the grant P27361-B23 from the Austrian Science Grant (FWF), FXR was supported by SAF2011-29530 and SAF2015-70553-R grants from Ministerio de Economía y Competitividad (Madrid, Spain) (co-funded by the ERDF-EU), Fundación Científica de la Asociación Española Contra el Cáncer. CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510. Work in the lab of JSC and CC was supported by Cancer Research UK. Work in the lab of SRM was supported by the Spanish Ministry of Science, Innovation and Universities (BFU2016-80570-R; AEI/FEDER, UE).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer

  • Martinelli, Paola
  • Carrillo, Enrique
  • Cox, Trevor
  • Sainz, Bruno Jr
  • Dusetti, Nelson
  • Greenhalf, William
  • Rinaldi, Lorenzo, 1986-
  • Costello, Eithne
  • Ghaneh, Paula
  • Malats i Riera, Núria
  • Büchler, Markus
  • Pajic, Marina
  • Biankin, Andrew V.
  • Iovanna, Juan
  • Neoptolemos, John
  • Real, Francisco X.
BACKGROUND AND AIMS: The role of GATA factors in cancer has gained increasing attention recently, but the function of GATA6 in pancreatic ductal adenocarcinoma (PDAC) is controversial. GATA6 is amplified in a subset of tumours and was proposed to be oncogenic, but high GATA6 levels are found in well-differentiated tumours and are associated with better patient outcome. By contrast, a tumour-suppressive function of GATA6 was demonstrated using genetic mouse models. We aimed at clarifying GATA6 function in PDAC. DESIGN: We combined GATA6 silencing and overexpression in PDAC cell lines with GATA6 ChIP-Seq and RNA-Seq data, in order to understand the mechanism of GATA6 functions. We then confirmed some of our observations in primary patient samples, some of which were included in the ESPAC-3 randomised clinical trial for adjuvant therapy. RESULTS: GATA6 inhibits the epithelial-mesenchymal transition (EMT) in vitro and cell dissemination in vivo. GATA6 has a unique proepithelial and antimesenchymal function, and its transcriptional regulation is direct and implies, indirectly, the regulation of other transcription factors involved in EMT. GATA6 is lost in tumours, in association with altered differentiation and the acquisition of a basal-like molecular phenotype, consistent with an epithelial-to-epithelial (ET2) transition. Patients with basal-like GATA6low tumours have a shorter survival and have a distinctly poor response to adjuvant 5-fluorouracil (5-FU)/leucovorin. However, modulation of GATA6 expression in cultured cells does not directly regulate response to 5-FU. CONCLUSIONS: We provide mechanistic insight into GATA6 tumour-suppressive function, its role as a regulator of canonical epithelial differentiation, and propose that loss of GATA6 expression is both prognostic and predictive of response to adjuvant therapy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/., This work was supported, in part, by grants SAF2007-60860, SAF2011-29530 and ONCOBIO Consolider from Ministerio de Economía y Competitividad (Madrid, Spain), RTICC from Instituto de Salud Carlos III, grants 256974 and 289737 from European Union Seventh Framework Program to FXR and by grant P27361-B23 from the Austrian Science Fund (FWF) to PM. AB receives support from the Wellcome Trust, Cancer Research UK, the Medical Research Council (MRC), The Engineering and Physical Sciences Research Council (EPSRC), Pancreatic Cancer UK, the Chief Scientists Office (Scottish Government) and Pancreatic Cancer Action Network (USA). The Cancer Research UK Liverpool Clinical Trials Unit, the ESPAC trials, and the ESPAC tissue collections, storage and analyses are all funded by Cancer Research UK. PM was recipient of a Juan de la Cierva grant from Spanish Ministry of Science and Innovation. BSJr is recipient of a Ramón y Cajal Merit Award from the Spanish Ministry of Science and Innovation and a Clinic and Laboratory Integration Program (CLIP) grant from the Cancer Research Institute, NY.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

AID-expressing epithelium is protected from oncogenic transformation by an NKG2D surveillance pathway

  • Pérez García, Arantxa
  • Pérez Durán, Pablo
  • Wossning, Thomas
  • Sernandez, Isora V.
  • Mur, Sonia M.
  • Cañamero, Marta
  • Real, Francisco X.
  • Ramiro, Almudena R.
Activation-induced deaminase (AID) initiates secondary antibody diversification in germinal center B cells, giving rise to higher affinity antibodies through somatic hypermutation (SHM) or to isotype-switched antibodies through class switch recombination (CSR). SHM and CSR are triggered by AID-mediated deamination of cytosines in immunoglobulin genes. Importantly, AID activity in B cells is not restricted to Ig loci and can promote mutations and pro-lymphomagenic translocations, establishing a direct oncogenic mechanism for germinal center-derived neoplasias. AID is also expressed in response to inflammatory cues in epithelial cells, raising the possibility that AID mutagenic activity might drive carcinoma development. We directly tested this hypothesis by generating conditional knock-in mouse models for AID overexpression in colon and pancreas epithelium. AID overexpression alone was not sufficient to promote epithelial cell neoplasia in these tissues, in spite of displaying mutagenic and genotoxic activity. Instead, we found that heterologous AID expression in pancreas promotes the expression of NKG2D ligands, the recruitment of CD8(+) T cells, and the induction of epithelial cell death. Our results indicate that AID oncogenic potential in epithelial cells can be neutralized by immunosurveillance protective mechanisms., AP‐G is a fellow of the research training program (FPU‐ AP2009‐1732) funded by the Ministerio de Educación, Cultura y Deporte, PP‐D was an FPI fellow from the Ministerio de Ciencia e Innovación. ARR is supported by Centro Nacional de Investigaciones Cardiovaculares (CNIC). This work was funded by grants from the Ministerio de Economía y Competitividad (SAF2010‐21394, SAF2013‐42767‐R) and the European Research Council Starting Grant program (BCLYM‐207844) to ARR. The CNIC is supported by the Ministerio de Economía y Competitividad and the Pro‐CNIC Foundation. FXR is supported by SAF2011‐29530 and ONCOBIO Consolider grants from Ministerio de Economía y Competitividad (Madrid, Spain), RTICC from Instituto de Salud Carlos III, and grant 256974 from European Union Seventh Framework Programme to FXR.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver

  • Hruschka, Natascha
  • Andreu Martínez, David
  • Real, Francisco X.
  • Martinelli, Paola
As the catalog of oncogenic driver mutations is expanding, it becomes clear that alterations in a given gene might have different functions and should not be lumped into one class. The transcription factor GATA3 is a paradigm of this. We investigated the functions of the most common GATA3 mutation (X308_Splice) and five additional mutations, which converge into a neoprotein that we called "neoGATA3," associated with excellent prognosis in patients. Analysis of available molecular data from >3000 breast cancer patients revealed a dysregulation of the ER-dependent transcriptional response in tumors carrying neoGATA3-generating mutations. Mechanistic studies in vitro showed that neoGATA3 interferes with the transcriptional programs controlled by estrogen and progesterone receptors, without fully abrogating them. ChIP-Seq analysis indicated that ER binding is reduced in neoGATA3-expressing cells, especially at distal regions, suggesting that neoGATA3 interferes with the fine tuning of ER-dependent gene expression. This has opposite outputs in distinct hormonal context, having pro- or anti-proliferative effects, depending on the estrogen/progesterone ratio. Our data call for functional analyses of putative cancer drivers to guide clinical application., Work in the lab of PM was supported by the Institute of Cancer Research of the Medical University Vienna and by the grant P27361-B23 from the Austrian Science Grant (FWF), FXR was supported by SAF2011-29530 and SAF2015-70553-R grants from Ministerio de Economía y Competitividad (Madrid, Spain) (co-funded by the ERDF-EU), Fundación Científica de la Asociación Española Contra el Cáncer. CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510. Work in the lab of JSC and CC was supported by Cancer Research UK. Work in the lab of SRM was supported by the Spanish Ministry of Science, Innovation and Universities (BFU2016-80570-R; AEI/FEDER, UE).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer

  • Kalisz, Mark
  • Bernardo, Edgar
  • Maestro, Miguel Ángel
  • Grau, Vanessa
  • Real, Francisco X.
  • Ferrer, Jorge
Defects in transcriptional regulators of pancreatic exocrine differentiation have been implicated in pancreatic tumorigenesis, but the molecular mechanisms are poorly understood. The locus encoding the transcription factor HNF1A harbors susceptibility variants for pancreatic ductal adenocarcinoma (PDAC), while KDM6A, encoding Lysine-specific demethylase 6A, carries somatic mutations in PDAC. Here, we show that pancreas-specific Hnf1a null mutant transcriptomes phenocopy those of Kdm6a mutations, and both defects synergize with KrasG12D to cause PDAC with sarcomatoid features. We combine genetic, epigenomic, and biochemical studies to show that HNF1A recruits KDM6A to genomic binding sites in pancreatic acinar cells. This remodels the acinar enhancer landscape, activates differentiated acinar cell programs, and indirectly suppresses oncogenic and epithelial-mesenchymal transition genes. We also identify a subset of non-classical PDAC samples that exhibit the HNF1A/KDM6A-deficient molecular phenotype. These findings provide direct genetic evidence that HNF1A deficiency promotes PDAC. They also connect the tumor-suppressive role of KDM6A deficiency with a cell-specific molecular mechanism that underlies PDAC subtype definition., This research was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre. Work was funded by grants from the Wellcome Trust (WT101033 to J.F.), Medical Research Council (MR/L02036X/1 to J.F.), European Research Council Advanced Grant (789055 to J.F.), Ministerio de Ciencia e Innovación (BFU2014‐54284‐R, RTI2018‐095666‐B‐I00 to J.F., SAF2011‐29530 and SAF2015‐70553‐R to F.X.R.) and RTICC from Instituto de Salud Carlos III (RD12/0036/0034, RD12/0036/0050) to F.X.R. M.K. was supported by a Juvenile Diabetes Research Foundation postdoctoral fellowship (3‐PDF‐2014‐192‐A‐N). I.M. was supported by a Fellowship from Fundació Bancaria La Caixa (ID 100010434) (grant number LCF/BQ/ES18/11670009). Work in CRG was supported by the CERCA Programme, Generalitat de Catalunya, and support from Ministerio de Ciencia e Innovación to the EMBL partnership. Work at CRG and CNIO was supported by Centro de Excelencia Severo Ochoa grants SEV‐2012‐0208, SEV‐2016‐0510.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer

  • Martinelli, Paola
  • Carrillo, Enrique
  • Cox, Trevor
  • Sainz, Bruno Jr
  • Dusetti, Nelson
  • Greenhalf, William
  • Rinaldi, Lorenzo, 1986-
  • Costello, Eithne
  • Ghaneh, Paula
  • Malats i Riera, Núria
  • Büchler, Markus
  • Pajic, Marina
  • Biankin, Andrew V.
  • Iovanna, Juan
  • Neoptolemos, John
  • Real, Francisco X.
BACKGROUND AND AIMS: The role of GATA factors in cancer has gained increasing attention recently, but the function of GATA6 in pancreatic ductal adenocarcinoma (PDAC) is controversial. GATA6 is amplified in a subset of tumours and was proposed to be oncogenic, but high GATA6 levels are found in well-differentiated tumours and are associated with better patient outcome. By contrast, a tumour-suppressive function of GATA6 was demonstrated using genetic mouse models. We aimed at clarifying GATA6 function in PDAC. DESIGN: We combined GATA6 silencing and overexpression in PDAC cell lines with GATA6 ChIP-Seq and RNA-Seq data, in order to understand the mechanism of GATA6 functions. We then confirmed some of our observations in primary patient samples, some of which were included in the ESPAC-3 randomised clinical trial for adjuvant therapy. RESULTS: GATA6 inhibits the epithelial-mesenchymal transition (EMT) in vitro and cell dissemination in vivo. GATA6 has a unique proepithelial and antimesenchymal function, and its transcriptional regulation is direct and implies, indirectly, the regulation of other transcription factors involved in EMT. GATA6 is lost in tumours, in association with altered differentiation and the acquisition of a basal-like molecular phenotype, consistent with an epithelial-to-epithelial (ET2) transition. Patients with basal-like GATA6low tumours have a shorter survival and have a distinctly poor response to adjuvant 5-fluorouracil (5-FU)/leucovorin. However, modulation of GATA6 expression in cultured cells does not directly regulate response to 5-FU. CONCLUSIONS: We provide mechanistic insight into GATA6 tumour-suppressive function, its role as a regulator of canonical epithelial differentiation, and propose that loss of GATA6 expression is both prognostic and predictive of response to adjuvant therapy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/., This work was supported, in part, by grants SAF2007-60860, SAF2011-29530 and ONCOBIO Consolider from Ministerio de Economía y Competitividad (Madrid, Spain), RTICC from Instituto de Salud Carlos III, grants 256974 and 289737 from European Union Seventh Framework Program to FXR and by grant P27361-B23 from the Austrian Science Fund (FWF) to PM. AB receives support from the Wellcome Trust, Cancer Research UK, the Medical Research Council (MRC), The Engineering and Physical Sciences Research Council (EPSRC), Pancreatic Cancer UK, the Chief Scientists Office (Scottish Government) and Pancreatic Cancer Action Network (USA). The Cancer Research UK Liverpool Clinical Trials Unit, the ESPAC trials, and the ESPAC tissue collections, storage and analyses are all funded by Cancer Research UK. PM was recipient of a Juan de la Cierva grant from Spanish Ministry of Science and Innovation. BSJr is recipient of a Ramón y Cajal Merit Award from the Spanish Ministry of Science and Innovation and a Clinic and Laboratory Integration Program (CLIP) grant from the Cancer Research Institute, NY.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

NFIC regulates ribosomal biology and ER stress in pancreatic acinar cells and restrains PDAC initiation

  • Cobo, Isidoro
  • Paliwal, Sumit
  • Bodas, Cristina
  • Felipe, Irene
  • Melià-Alomà, Júlia
  • Torres, Ariadna
  • Martínez-Villarreal, Jaime
  • Malumbres, Marina
  • García, Fernando
  • Millán, Irene
  • Del Pozo, Natalia
  • Park, Joo-Cheol
  • MacDonald, Ray J.
  • Muñoz, Javier
  • Méndez, Raúl
  • Real, Francisco X.
Pancreatic acinar cells rely on PTF1 and other transcription factors to deploy their transcriptional program. We identify NFIC as a NR5A2 interactor and regulator of acinar differentiation. NFIC binding sites are enriched in NR5A2 ChIP-Sequencing peaks. Nfic knockout mice have a smaller, histologically normal, pancreas with reduced acinar gene expression. NFIC binds and regulates the promoters of acinar genes and those involved in RNA/protein metabolism, and Nfic knockout pancreata show defective ribosomal RNA maturation. NFIC dampens the endoplasmic reticulum stress program through binding to gene promoters and is required for resolution of Tunicamycin-mediated stress. NFIC is down-regulated during caerulein pancreatitis and is required for recovery after damage. Normal human pancreata with low levels of NFIC transcripts display reduced expression of genes down-regulated in Nfic knockout mice. NFIC expression is down-regulated in mouse and human pancreatic ductal adenocarcinoma. Consistently, Nfic knockout mice develop a higher number of mutant Kras-driven pre-neoplastic lesions., This work was supported, in part, by grants SAF2011-29530, SAF2015-70553-R, RTI2018-101071-B-I00 from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (co-funded by the ERDF-EU) and RTICC from Instituto de Salud Carlos III (RD12/0036/0034) to FXR and grants PID2020-119533GB-I00, from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain), and GCB15152955MÉND, from the Spanish Association Against Cancer (AECC), to RM. I.C. was recipient of a Beca de Formación del Personal Investigador from Ministerio de Economía y Competitividad (Madrid, Spain). The research leading to these results has received funding from People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007-2013) (REA grant agreement n° 608765”). S.P. was supported by a Juan de la Cierva Programme fellowship from Ministerio de Ciencia, Innovación y Universidades. C.B. is supported by a FPI Fellowship from Ministerio de Ciencia, Innovación y Universidades. I.M. was supported by a Fellowship from Fundació Bancària La Caixa (ID 100010434) (grant number LCF/BQ/ES18/11670009). CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510.